FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer
Full article:

The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This  approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at treatment for people with metastatic HER2-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.